Alto Ingredients, Inc.

NasdaqCM:ALTO 株式レポート

時価総額：US$361.9m

Alto Ingredients 過去の業績

過去 基準チェック /36

Alto Ingredientsの収益は年間平均-29.6%の割合で減少していますが、 Chemicals業界の収益は年間 減少しています。収益は年間4% 3.7%割合で 減少しています。 Alto Ingredientsの自己資本利益率は11.7%であり、純利益率は3.1%です。

主要情報

-29.59%

収益成長率

-29.85%

EPS成長率

Chemicals 業界の成長12.93%
収益成長率-3.75%
株主資本利益率11.72%
ネット・マージン3.06%
前回の決算情報31 Mar 2026

最近の業績更新

Recent updates

ナラティブの更新 • May 15

ALTO: Future Returns Will Hinge On MASH Trials And Alcohol Liver Data

Alto Ingredients' analyst price target has been revised higher to $8.00 from $4.50, with analysts citing updated assumptions about the discount rate, revenue growth, profit margin, and future P/E to reflect recent research on the company's pipeline and market opportunities. Analyst Commentary While the revised US$8.00 price target reflects updated assumptions about Alto Ingredients' potential, some of the broader Street research on comparable stocks highlights why not all analysts are leaning in aggressively on valuation.
ナラティブの更新 • Apr 23

ALTO: MASH And Alcohol-Related Liver Programs Will Drive Future Upside Potential

Alto Ingredients' analyst fair value estimate has shifted from $4.00 to $6.75 as analysts factor in updated assumptions on discount rate, revenue growth, margins, and a higher future P/E in light of recent bullish coverage and revised price targets tied to pemvidutide's MASH and alcohol-related disease programs. Analyst Commentary Bullish Takeaways Bullish analysts are focused on pemvidutide as a differentiated asset for MASH and alcohol-related liver disease.
ナラティブの更新 • Apr 09

ALTO: Future Returns Will Depend On MASH Trials And Alcohol Liver Data

Analysts have raised Alto Ingredients' price target to $25 from $12, citing pemvidutide's potential in MASH and alcohol-related liver and use disorders as key factors behind the revision. Analyst Commentary Recent Street research on Alto Ingredients highlights a mixed backdrop, with optimistic views on pemvidutide and the MASH program set against more cautious assessments of risk and valuation.
ナラティブの更新 • Mar 26

ALTO: Future Returns Will Hinge On MASH Trials And Funding Discipline

Analysts have raised their average price target for Alto Ingredients to $25 from $12, citing a sharpened focus on the planned MASH pivotal program and added potential value from pemvidutide in alcohol use disorder and alcohol liver disease, along with a solid cash runway and upcoming clinical catalysts. Analyst Commentary Recent Street research on Altimmune reflects a mix of optimism around the clinical pipeline and caution around execution risks and valuation.
ナラティブの更新 • Mar 11

ALTO: Future Returns Will Depend On Execution And Funding Discipline

Analysts have raised their price target on Alto Ingredients to $4.50 from $3.00, citing updated assumptions around fair value, discount rate, expected revenue growth, profit margins, and future P/E that they say are more in line with recent Street research on comparable companies. Analyst Commentary While the higher price target reflects updated valuation work, some bearish analysts in the broader small cap space are still emphasizing execution and funding risks that can weigh on sentiment for companies like Alto Ingredients.
ナラティブの更新 • Feb 25

ALTO: Future Upside Will Depend On Delivering Consistent Margin Execution

Analysts have adjusted their price target on Alto Ingredients to $3.00, with the neutral fair value and updated assumptions on discount rate, revenue growth, profit margin, and future P/E reflecting a refined view of the company’s risk and earnings profile following recent supportive research coverage. Analyst Commentary Recent research on Alto Ingredients has focused on reassessing the balance between potential upside and the risks tied to execution, earnings quality, and market conditions.
ナラティブの更新 • Feb 11

ALTO: Fair Outlook Will Rely On Sustaining Margins And Execution

Analysts have raised their price target for Alto Ingredients to US$3.00, reflecting updated views that include modestly higher revenue growth, slightly stronger profit margins, a lower discount rate, and a revised future P/E assumption, supported in part by recent bullish Street research. Analyst Commentary While the updated US$3.00 price target points to a more constructive stance overall, some bearish analysts remain cautious and continue to flag risk around how Alto Ingredients can justify this valuation through execution and earnings delivery.
ナラティブの更新 • Jan 27

ALTO: Upcoming Liver Meeting Data Will Support Repriced Risk Reward Profile

Analysts recently trimmed their 12 month price target on Alto Ingredients by US$1 to US$14, citing refreshed assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts trimming price targets on comparable small cap names to around US$14, even when maintaining constructive ratings, suggest a tighter margin for error around assumptions such as discount rates, revenue growth, profit margins, and future P/E multiples.
ナラティブの更新 • Jan 12

ALTO: Upcoming Late-Stage Liver Data Will Support Repriced Risk Reward Profile

Narrative Update: Alto Ingredients Analyst Price Target Shift Analysts have trimmed their price target on Alto Ingredients by $1 to $14, citing updated risk and growth assumptions after the timing and outlook of recent clinical data were refined. Analyst Commentary Recent Street research reflects a more cautious tone, with bearish analysts trimming price targets and rechecking their assumptions on risk and potential upside.
ナラティブの更新 • Dec 26

ALTO: Upcoming Late-Stage Data Will Shape Risk Profile Amid Measured Outlook

Analysts have modestly lowered their price target on Alto Ingredients, trimming fair value by $1 to $14 as they factor in slightly softer long term assumptions, while remaining encouraged by upcoming late stage data presentations. Analyst Commentary Bearish analysts have pointed to the recent price target reduction to $14 as evidence that expectations for Alto Ingredients' long term growth and profitability are being tempered, even as upcoming late stage data remains a potential catalyst.
分析記事 • Dec 22

Alto Ingredients, Inc.'s (NASDAQ:ALTO) Shares Leap 41% Yet They're Still Not Telling The Full Story

Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 41% gain in the last month...
ナラティブの更新 • Dec 12

ALTO: Lower Discount Rate Will Support Improved Risk Profile Ahead

Analysts have raised their price target on Alto Ingredients by about $0.50, citing a lower perceived risk profile driven by a reduced discount rate, stronger expected revenue growth, and a modest improvement in projected profit margins and future valuation multiples. Analyst Commentary Bearish analysts remain cautious on Alto Ingredients despite the recent upward revision to the price target, emphasizing that the new target still embeds a meaningful discount to peers on key growth and profitability metrics.
分析記事 • Nov 07

Alto Ingredients, Inc. (NASDAQ:ALTO) Shares Fly 28% But Investors Aren't Buying For Growth

Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 28% gain in the last month...
分析記事 • Jul 04

Alto Ingredients, Inc. (NASDAQ:ALTO) Held Back By Insufficient Growth Even After Shares Climb 31%

Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 31% gain in the last month...
User avatar
新しいナラティブ • May 04

CO2 Plant Integration Will Boost Production And Exports

Acquisition and integration of the CO2 processing plant are expected to improve financials through cost synergies, increased capacity, and enhanced revenue streams.
分析記事 • Apr 22

Health Check: How Prudently Does Alto Ingredients (NASDAQ:ALTO) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Nov 12

Alto Ingredients (NASDAQ:ALTO) Is Making Moderate Use Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Jul 17

Alto Ingredients, Inc.'s (NASDAQ:ALTO) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Alto Ingredients, Inc. ( NASDAQ:ALTO ) shareholders are no doubt pleased to see that the share price has bounced 26% in...
分析記事 • Jun 28

Would Alto Ingredients (NASDAQ:ALTO) Be Better Off With Less Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Jan 15

Here's Why Alto Ingredients (NASDAQ:ALTO) Can Afford Some Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
分析記事 • Dec 20

Alto Ingredients, Inc. (NASDAQ:ALTO) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Those holding Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares would be relieved that the share price has rebounded 25% in...
分析記事 • Sep 15

Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Apr 10

We Think Alto Ingredients (NASDAQ:ALTO) Has A Fair Chunk Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
分析記事 • Dec 16

Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Oct 19

Alto Ingredients: The Decline Has Created A Buying Opportunity

Summary Alto Ingredients has experienced some downward pressure over the past few months, even in spite of growing revenue and profits. Some of the bottom-line figures are deceptive given the role that a grant played in the matter, but the overall picture is still improving. Risk appears fairly low and shares look attractively priced right now. Just because an investment didn't offer attractive prospects at one point in time doesn't mean that the picture can't change for the better. As strong performance continues to be demonstrated and as shares of a company decline in price, the attractiveness of the firm in question can become more appealing, eventually reaching the point that assigning it a ‘buy’ rating just makes sense. One example of this can be seen by looking at Alto Ingredients (ALTO), a firm that produces and markets specialty alcohols and other essential ingredients for its customers. Recently, shares of the company have fallen even as fundamental performance remains strong. In addition to shares getting cheaper, the company continues to have cash in excess of debt totaling $22.2 million, leaving it with a good amount of wiggle room should market conditions worsen. Long term, investors should still expect significant volatility from a fundamental perspective. But given where shares are priced today, I do feel comfortable increasing my rating on the firm from a ‘hold’ to a ‘buy’, reflecting my opinion that the company’s stock should outperform the broader market for the foreseeable future. Robust strength changed my opinion Back in July of this year, I wrote an article that looked upon Alto Ingredients in a very neutral way. In truth, I was turned off by the volatility the company had seen in prior years, especially when it came to profitability. Having said that, profits in 2020 and 2021 proved to be rather robust for the company thanks to the change in market conditions. These changes, combined with a refusal by the market to push shares higher, leads into the stock looking rather cheap. But I still couldn't get over the company's business model and volatility as risk factors, ultimately resulting in a ‘hold’ rating for the business. Since then, shares of the firm have performed slightly better than I would have anticipated. While the S&P 500 has dropped by 12.9%, Alto Ingredients has seen a drop of 9.8%. Author - SEC EDGAR Data This return disparity is not necessarily large enough to be anything more than statistical noise. Having said that, it is also true that the company has continued to generate strong fundamental growth during this window of time. To see what I mean, we need only look at results covering the second quarter of the company's 2022 fiscal year. This is the only quarter for which data is now available that was not available when I last wrote about it. During that quarter, revenue came in at $362.2 million. That's 21.5% higher than the $298.1 million generated the same quarter only one year earlier. Total gallons of specialty alcohols the company sold actually dropped, declining from 125 million to 107.1 million. However, the firm did benefit from an increase in average pricing per gallon from $2.41 to $2.84. This drop in gallons sold was largely driven by a reduction in 3rd party gallons as the company continued to focus on the marketing and sales efforts associated with its own core production assets. The company also saw a more than doubling of sales of alcohol from its other production segment, driven by a rise in gallons sold of 14.4 million. This represents a 176% rise year over year. That unit also benefited from a $0.27 per gallon increase year over year. Meanwhile, essential ingredients revenue jumped by 221% to $23.4 million, driven by a 140% rise in volume and a 34% increase in average sales price per ton. Author - SEC EDGAR Data Clearly, the company's growth initiatives, particularly with regard to its emphasis on its own core production and to expanding into the specialty alcohols and essential ingredients spaces have proven to be beneficial for shareholders. The end result has also been an improvement in profitability. Net income in the second quarter of this year totaled $22.1 million. That's significantly higher than the $8.4 million reported one year earlier. Operating cash flow rose from $8.5 million to $9.6 million. But if we adjust for changes in working capital, the picture would have been even better, with the metric growing from $24.2 million to $38.4 million. Meanwhile, EBITDA also improved, rising from $17 million to $29.9 million. It is worth mentioning that profitability for the company was somewhat skewed. Although revenue has been rising, the firm benefited to the tune of $22.7 million from a grant associated with the USDA. Without that, operating income would have actually declined from $6.1 million in the second quarter of 2021 to negative $0.15 million the same time this year. It is worth mentioning that total results for the first half of the year did also come in stronger than what the company achieved in the first half of 2021. This much can be seen in the chart above. Author - SEC EDGAR Data Unfortunately, we don't really know what to expect for the rest of the current fiscal year. Given the one-time nature of the grant I mentioned, it's difficult to know what the organic potential the firm is. So instead of projecting out what results might look like for the rest of the year, I decided to price the company using data from 2021. Using this approach, the firm is trading at a price to adjusted operating cash flow multiple of 6.9 and at an EV to EBITDA multiple of 3.4. As part of my analysis, I compared the company to two other firms that are somewhat similar in nature. On a price to operating cash flow basis, these companies traded at multiples of 1.5 and 15.3. And using the EV to EBITDA approach, the multiples were 0.6 and 6.3. In both cases, our prospect was in the middle of the two.
Seeking Alpha • Sep 12

Alto Ingredients gains on announcing $50M share repurchase program

Alto Ingredients (NASDAQ:ALTO) climbs on 4.76% premarket on authorizing share repurchase program for up to $ 50M of its common stock with an initial purchase authorization of $10M. “Given our positive long-term outlook, we believe our shares are currently undervalued. Based on the strength of our balance sheet, an opportunity exists to create value for our stockholders by repurchasing stock while we continue to upgrade our equipment and operating systems to increase efficiency and plant reliability, expand our corn storage capacity, enhance our specialty alcohol production, broaden our distribution, and reinvest in essential ingredients capabilities,” said Michael Kandris, CEO of Alto Ingredients.
分析記事 • Aug 31

Alto Ingredients (NASDAQ:ALTO) Seems To Use Debt Quite Sensibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

収支内訳

Alto Ingredients の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:ALTO 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 2691628270
31 Dec 2591812270
30 Sep 25922-51280
30 Jun 25933-68240
31 Mar 25951-60300
31 Dec 24965-60300
30 Sep 241,003-37280
30 Jun 241,069-39320
31 Mar 241,150-28290
31 Dec 231,223-29300
30 Sep 231,278-43340
30 Jun 231,297-68320
31 Mar 231,341-53320
31 Dec 221,336-43280
30 Sep 221,39326310
30 Jun 221,36151300
31 Mar 221,29737300
31 Dec 211,20844290
30 Sep 21991-12270
30 Jun 218907270
31 Mar 2180413290
31 Dec 20897-16320
30 Sep 201,086-37370
30 Jun 201,246-80390
31 Mar 201,380-102370
31 Dec 191,425-90350
30 Sep 191,402-81330
30 Jun 191,407-61330
31 Mar 191,471-67350
31 Dec 181,515-62360
30 Sep 181,576-43360
30 Jun 181,651-36360
31 Mar 181,646-31350
31 Dec 171,632-36350
30 Sep 171,679-10380
30 Jun 171,651-13350
31 Mar 171,6691330
31 Dec 161,6250320
30 Sep 161,560-14260
30 Jun 161,523-25280
31 Mar 161,327-29250
31 Dec 151,191-20250
30 Sep 151,071-7200
30 Jun 1596611170

質の高い収益: ALTOは 高品質の収益 を持っています。

利益率の向上: ALTO過去に利益を上げました。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ALTO過去 5 年間で収益を上げており、収益は年間-29.6%増加しています。

成長の加速: ALTOは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: ALTO昨年収益を上げたため、昨年の収益成長をChemicals業界 ( -1.4% ) と比較することは困難です。

株主資本利益率

高いROE: ALTOの 自己資本利益率 ( 11.7% ) は 低い とみなされます。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/21 11:42
終値2026/05/21 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Alto Ingredients, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9

アナリスト機関
Carter DriscollB. Riley Securities, Inc.
Hamed KhorsandBWS Financial Inc.
Eric StineCraig-Hallum Capital Group LLC